Our top pick for
Building a portfolio
Omnicell, Inc is a health information services business based in the US. Omnicell shares (OMCL) are listed on the NASDAQ and all prices are listed in US Dollars. Omnicell employs 2,860 staff and has a trailing 12-month revenue of around USD0.00.
|52-week range||USD$56.16 - USD$146|
|50-day moving average||USD$133.1882|
|200-day moving average||USD$113.3314|
|Wall St. target price||USD$138.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.74|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Omnicell stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Omnicell's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Omnicell's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 185x. In other words, Omnicell shares trade at around 185x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Omnicell's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.28. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Omnicell's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Omnicell's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$90 million.
The EBITDA is a measure of a Omnicell's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$892.2 million|
|Operating margin TTM||5.83%|
|Gross profit TTM||USD$415.9 million|
|Return on assets TTM||2.12%|
|Return on equity TTM||3.55%|
|Market capitalisation||USD$5.9 billion|
TTM: trailing 12 months
There are currently 2.2 million Omnicell shares held short by investors – that's known as Omnicell's "short interest". This figure is 10.2% up from 2.0 million last month.
There are a few different ways that this level of interest in shorting Omnicell shares can be evaluated.
Omnicell's "short interest ratio" (SIR) is the quantity of Omnicell shares currently shorted divided by the average quantity of Omnicell shares traded daily (recently around 556870.63291139). Omnicell's SIR currently stands at 3.95. In other words for every 100,000 Omnicell shares traded daily on the market, roughly 3950 shares are currently held short.
However Omnicell's short interest can also be evaluated against the total number of Omnicell shares, or, against the total number of tradable Omnicell shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Omnicell's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Omnicell shares in existence, roughly 50 shares are currently held short) or 0.07% of the tradable shares (for every 100,000 tradable Omnicell shares, roughly 70 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Omnicell.
Find out more about how you can short Omnicell stock.
We're not expecting Omnicell to pay a dividend over the next 12 months.
Over the last 12 months, Omnicell's shares have ranged in value from as little as $56.16 up to $146. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omnicell's is 1.027. This would suggest that Omnicell's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Omnicell, Inc. , together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.